Search - tctmd.com

Displaying 281 - 300 of 327

Sort: Relevancy | Date

Presentation TCT 2016

Severe AS and Chronic Kidney Disease

Presenter: Howard C. Herrmann, Vinod H. Thourani, Molly Szerlip

October 31, 2016

Presentation TCT 2016

Severe AS and COPD

Presenter: Howard C. Herrmann, Vinod H. Thourani, Kendra J. Grubb

October 31, 2016

Presentation TCT 2016

Low-gradient AS Diagnosis and Management

Presenter: Howard C. Herrmann, Vinod H. Thourani, Allan Schwartz

October 31, 2016

Presentation TCT 2016

Severe AS With a Small Aortic Annulus

Presenter: Howard C. Herrmann, Vinod H. Thourani, Josep Rodés-Cabau

October 31, 2016

Presentation TCT 2016

Severe AS and LV Dysfunction

Presenter: Howard C. Herrmann, Vinod H. Thourani, G. Michael Deeb

October 31, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research VI: Updates From the NOTION Randomized All-Comers Trial

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research V: Updates From U.S. TVT Registry Newest Findings

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, John D. Carroll

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research IV: Updates From FRANCE 2 Registry

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Helene Eltchaninoff

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research III: Updates From Italian Registries and OBSERVANT

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Corrado Tamburino

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Neil E. Moat

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research I: Updates From GARY and Other German Registries

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Thomas Walther

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Poor Femoral Access

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Richard Smalling

October 30, 2016

Presentation TCT 2016

Severe AS and Extreme Co-morbidities (Futile Patient?)

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Suzanne V. Arnold

October 30, 2016

Presentation TCT 2016

Management of Failing Aortic Bioprosthesis

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Danny Dvir

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Atrial Fibrillation

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Fabian Nietlispach

October 30, 2016

Presentation TCT 2016

My Rosy Prophecy: What Will the Specialty of Mitral Valve Therapeutics Look Like in 10 Years?

Presenter: James S. Gammie, James B. Hermiller Jr., Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Surgical Mitral Valve Repair Or Replacement Via A Minimally Invasive Approach Will Be The Gold Standard!

Presenter: James S. Gammie, James B. Hermiller Jr., Steven F. Bolling

October 30, 2016

Presentation TCT 2016

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? No, The Bar Is Too High Transcatheter Mitral Repair Will Always Be Safer And Nearly As Effective!

Presenter: James S. Gammie, James B. Hermiller Jr., Ted Feldman

October 30, 2016

Presentation TCT 2016

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Transcatheter MV Replacement Will Become Standard Of Care For Secondary MR!

Presenter: James S. Gammie, James B. Hermiller Jr., Stephan Windecker

October 30, 2016

Presentation TCT 2016

First Debate: Should The Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely Not - In No Universe Would That Be Considered Acceptable Care!

Presenter: James S. Gammie, James B. Hermiller Jr., Alfredo Trento

October 30, 2016

Advertisement

Severe AS and Chronic Kidney Disease

Severe AS and COPD

Low-gradient AS Diagnosis and Management

Severe AS With a Small Aortic Annulus

Severe AS and LV Dysfunction

Key Contributions to TAVR Clinical Research VI: Updates From the NOTION Randomized All-Comers Trial

Key Contributions to TAVR Clinical Research V: Updates From U.S. TVT Registry Newest Findings

Key Contributions to TAVR Clinical Research IV: Updates From FRANCE 2 Registry

Key Contributions to TAVR Clinical Research III: Updates From Italian Registries and OBSERVANT

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

Key Contributions to TAVR Clinical Research I: Updates From GARY and Other German Registries

TAVR in Patients With Poor Femoral Access

Severe AS and Extreme Co-morbidities (Futile Patient?)

Management of Failing Aortic Bioprosthesis

TAVR in Patients With Atrial Fibrillation

My Rosy Prophecy: What Will the Specialty of Mitral Valve Therapeutics Look Like in 10 Years?

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Surgical Mitral Valve Repair Or Replacement Via A Minimally Invasive Approach Will Be The Gold Standard!

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? No, The Bar Is Too High Transcatheter Mitral Repair Will Always Be Safer And Nearly As Effective!

Second Debate: In 10 Years, How Will We Treat Most Patients With Secondary MR? Transcatheter MV Replacement Will Become Standard Of Care For Secondary MR!

First Debate: Should The Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely Not - In No Universe Would That Be Considered Acceptable Care!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content